SCHEMBL3037890

SCHEMBL3037890

COc1ccc(-c2cccc([N+](=O)[O-])c2)c2sc(C(N)=O)nc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKR1C3 P42330 1/20 0.49
▸ AKR1C2 P52895 1/20 0.49
▸ TUBB4A P04350 3/20 0.45
▸ TUBB P07437 3/20 0.45
▸ TUBA3C P0DPH7 3/20 0.45
▸ TUBA1B P68363 3/20 0.45
▸ TUBA4A P68366 3/20 0.45
▸ TUBB4B P68371 3/20 0.45
▸ TUBB3 Q13509 3/20 0.45
▸ TUBB2A Q13885 3/20 0.45
▸ TUBB8 Q3ZCM7 3/20 0.45
▸ TUBA3E Q6PEY2 3/20 0.45
▸ TUBA1A Q71U36 3/20 0.45
▸ TUBA1C Q9BQE3 3/20 0.45
▸ TUBB6 Q9BUF5 3/20 0.45
▸ TUBB2B Q9BVA1 3/20 0.45
▸ TUBB1 Q9H4B7 3/20 0.45
▸ KMO O15229 4/20 0.44
▸ L3MBTL1 Q9Y468 2/20 0.44
▸ PDE4D Q08499 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3037892 0.86 ADORA1 (0.47) AKR1C3AKR1C2TUBB4ATUBBTUBA3C
SCHEMBL3053212 0.84 DYRK1A (0.41) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL3052027 0.82 ACACA (0.47) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL3046561 0.81 FYN (0.47) PDE4DSMN1; SMN2RAB9A
SCHEMBL3050885 0.78 MKNK1 (0.56) MAPTMEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL3057520 0.76 CDC7 (0.47) PDE4DMAPTALDH1A1SMN1; SMN2
SCHEMBL3051200 0.74 CHRM4 (0.42) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL7499802 0.73 ABCB1 (0.54) AKR1C3AKR1C2TUBB4ATUBBTUBA3C
SCHEMBL7614440 0.73 TSHR (0.57) AKR1C3AKR1C2TUBB4ATUBBTUBA3C
SCHEMBL5581996 0.72 AKR1C3 (0.46) AKR1C3AKR1C2KMOL3MBTL1PDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100075959-A1 BENZOTHIAZOLE DERIVATIVES WITH ACTIVITY AS ADENOSINE RECEPTOR LIGANDS ALANINE ALEXANDER 2010-03-25 — — US disclosed
US-20080125419-A1 BENZOTHIAZOLE DERIVATIVES WITH ACTIVITY AS ADENOSINE RECEPTOR LIGANDS ALANINE ALEXANDER 2008-05-29 — — US disclosed
US-20080108809-A1 BENZOTHIAZOLE DERIVATIVES WITH ACTIVITY AS ADENOSINE RECEPTOR LIGANDS ALANINE ALEXANDER 2008-05-08 — — US disclosed
US-7317007-B2 Benzothiazole derivatives with activity as adenosine receptor ligands HOFFMANN-LA ROCHE INC. (US) 2008-01-08 — — US disclosed
EP-1797878-A2 Benzothiazole derivatives F. Hoffmann-La Roche AG (CH) 2007-06-20 — — EP disclosed
US-20060003986-A1 Benzothiazole derivatives with activity as adenosine receptor ligands ALANINE ALEXANDER 2006-01-05 — — US disclosed
US-6963000-B2 Benzothiazole derivatives with activity as adenosine receptor ligands HOFFMAN-LA ROCHE INC. (US) 2005-11-08 — — US disclosed
US-20050026906-A1 Benzothiazole derivatives with actitvity as adenosine receptor ligands ALANINE ALEXANDER (FR) 2005-02-03 — — US disclosed
US-6835732-B2 Modulation of the adenosine A2A receptor; cardioprotective agents; antiischemic agents; antihypoxia agents; central nervous system disorders, Alzheimer's disease, Parkinson's disease, anxiolytic agents; antidepressants; analgesics HOFFMAN-LA ROCHE INC. 2004-12-28 — — US disclosed
US-20030176695-A1 Benzothiazole derivatives with activity as adenosine receptor ligands ALANINE ALEXANDER (FR) 2003-09-18 — — US disclosed
US-20030125318-A1 Benzothiazole derivatives with activity as adenosine receptor ligands ALANINE ALEXANDER (FR) 2003-07-03 — — US disclosed
EP-1303272-A2 BENZOTHIAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-04-23 — — EP disclosed
US-6521754-B2 Such as N-4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-methyl-isoni cotinamide HOFFMAN-LA ROCHE INC. 2003-02-18 — — US disclosed
US-20020045615-A1 Benzothiazole derivatives with activity as adenosine receptor ligands F.HOFFMANN-LA ROCHE AG (CH) 2002-04-18 — — US disclosed
WO-2001097786-A2 BENZOTHIAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2001-12-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060003986-A1 Benzothiazole derivatives with activity as adenosine receptor ligands ADORA2A, ADORA1, ADORA3 AKR1C3 1579/4885AKR1C2 1336/4885TUBB4A 3360/4885
US-20080108809-A1 BENZOTHIAZOLE DERIVATIVES WITH ACTIVITY AS ADENOSINE RECEPTOR LIGANDS ADORA2A, ADORA1, ADORA3 AKR1C3 1579/4885AKR1C2 1336/4885TUBB4A 3360/4885
US-20080125419-A1 BENZOTHIAZOLE DERIVATIVES WITH ACTIVITY AS ADENOSINE RECEPTOR LIGANDS ADORA2A, ADORA1, ADORA3 AKR1C3 1746/4885AKR1C2 1484/4885TUBB4A 3382/4885
US-20030125318-A1 Benzothiazole derivatives with activity as adenosine receptor ligands ADORA2A, ADORA1, ADORA3 AKR1C3 1579/4885AKR1C2 1336/4885TUBB4A 3360/4885
US-20030176695-A1 Benzothiazole derivatives with activity as adenosine receptor ligands ADORA2A, ADORA1, ADORA3 AKR1C3 1579/4885AKR1C2 1336/4885TUBB4A 3360/4885
US-20050026906-A1 Benzothiazole derivatives with actitvity as adenosine receptor ligands ADORA2A, ADORA1, ADORA3 AKR1C3 1522/4885AKR1C2 1217/4885TUBB4A 2135/4885
US-20100075959-A1 BENZOTHIAZOLE DERIVATIVES WITH ACTIVITY AS ADENOSINE RECEPTOR LIGANDS ADORA2A, ADORA1, ADORA3 AKR1C3 1746/4885AKR1C2 1484/4885TUBB4A 3382/4885
US-20020045615-A1 Benzothiazole derivatives with activity as adenosine receptor ligands ADORA2A, ADORA1, ADORA3 AKR1C3 1579/4885AKR1C2 1336/4885TUBB4A 3360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback